Serum coenzyme Q10 and risk of disabling dementia: The Circulatory Risk in Communities Study (CIRCS)

Kazumasa Yamagishi a, c, *, Ai Ikeda d, Yuri Moriyama e, Choy-Lye Chei a, f, Hiroyuki Noda e, Mitsumasa Umesawa a, g, Renzhe Cui c, Masanori Nagao c, g, Akihiko Kitamura c, e, Yorihiro Yamamoto h, Takashi Asada h, Hiroyasu Iso c, for the CIRCS Investigators

a Department of Public Health Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
b Department of Psychiatry, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
c Osaka Center for Cancer and Cardiovascular Disease Prevention, Osaka, Japan
d Department of Public Health, Juntendo University, Tokyo, Japan
e Health Services and Systems Research, Duke-National University of Singapore Graduate Medical School, Singapore, Singapore
f Department of Public Health, Dokkyo Medical University, Mibu, Japan
g Department of Public Health Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
h School of Bioscience and Biotechnology, Tokyo University of Technology, Hachioji, Japan

ARTICLE INFO

Article history:
Received 19 March 2014
Received in revised form 30 August 2014
Accepted 20 September 2014
Available online 28 September 2014

Keywords:
Coenzyme Q10
Antioxidant
Dementia
Epidemiology
Follow-up study

ABSTRACT

Objective: To examine whether coenzyme Q10, a potent antioxidant, is associated with risk of dementia, which has not yet been elucidated. Approach and results: We performed a case–control study nested in a community-based cohort of approximately 6000 Japanese aged 40–69 years at baseline (1984–1994). Serum coenzyme Q10 was measured in 65 incident cases of disabling dementia with dementia-related behavioral disturbance or cognitive impairment incident between 1999 and 2004, and in 130 age-, sex- and baseline year-matched controls. Serum coenzyme Q10 was inversely associated with dementia: the multivariate odds ratios (95% confidence intervals) were 0.68 (0.26–1.78), 0.92 (0.33–2.56), and 0.23 (0.06–0.86) for individuals with the second, third, and highest quartiles of coenzyme Q10, respectively, as compared with the lowest quartile (P for trend = 0.05). A similar association was found for the coenzyme Q10/total cholesterol ratio: the respective ORs were 0.67 (0.25–1.78), 0.73 (0.28–1.92), and 0.21 (0.05–0.90) (P for trend = 0.04). Conclusions: Serum coenzyme Q10 levels were inversely associated with risk of disabling dementia.

© 2014 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Coenzyme Q10 (CoQ10), or ubiquinone, is a vitamin-like substance synthesized by animal cells. CoQ10 largely exists in the myocardium and plays a role in mitochondrial energy production. It also has an antioxidant function and is widely consumed as a supplement in the United States [1]. In addition to the prescription of CoQ10 as an orphan drug for mitochondrial encephalomyopathy, some evidence exists for a beneficial effect of CoQ10 on several neurologic diseases such as Parkinson disease [2], Huntington disease [3], and Friedreich ataxia [4,5] as well as on improved physical exercise capacity [6] and lowered blood pressure [6,7]. Animal studies have shown a potential benefit of CoQ10 on cognitive function [8–11]. A randomized controlled trial, however, has shown that the supplementation of CoQ10 did not influence cerebrospinal fluid biomarkers in patients with mild-to-moderate Alzheimer disease [12]. Yet, evidence on this issue is still limited, and no prospective study has been performed on the preventive effect of CoQ10 on risk of incident dementia in the general population.

In the present study, we hypothesized that because of its antioxidant effect, serum level of CoQ10 is inversely associated with disabling dementia. To test this hypothesis, we conducted a nested case–control study in the Circulatory Risk in Communities Study (CIRCS), a large community-based cohort study of Japanese population.

* Corresponding author. Department of Public Health Medicine, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba 305-8575, Japan.
E-mail address: yamagishi.kazumas.ge@u.tsukuba.ac.jp (K. Yamagishi).
2. Materials and methods

The CIRCS is an ongoing dynamic community cohort study involving 5 communities in Japan. Details of the CIRCS protocol have been described elsewhere [13]. In this study, we included only 1 community, Kyowa, where disabling dementia surveillance was being carried out, and serum CoQ10 values have been measured. A total of 653 cases of patients who were diagnosed between 1999 and 2004 as having disabling dementia, participated in annual health checkups (baseline) at least 5 years before receiving the dementia diagnosis (ie, between 1984 and 1994), were aged 40–69 years at baseline, and provided sera for storage at baseline were identified. The criteria of disabling dementia were the same as those of our previous study [14], which also includes the validation of the criteria and the details of the study protocol. As supplemental analysis, we further classified the dementia cases into cases with and without history of stroke on the basis of the systematic stroke registration system described elsewhere [4]. We excluded individuals aged 70 years or older at baseline, because serum CoQ10 would be likely affected by the baseline age, and residents aged 70 years and over were not invited systematically to the baseline examination. One hundred thirty randomly selected controls whose age (±3 years), sex, and follow-up time were matched at a ratio of 2:1, the cases were also identified from the risk set. Venous blood was collected at baseline, and sera were prepared from the blood samples as soon as possible after the blood collection at the checkup sites. The serum samples were collected in 0.3 mL tubes and stored at −80 °C until measurement in 2005. Serum CoQ10 was measured using high-performance liquid chromatography (HPLC) at the Public Health Institute of Kochi Prefecture with modification of the reported methods [15]. Briefly, a 10 μL serum sample was pretreated with 380 μL of 2-propanol. After centrifugation at 7000 g for 5 min, 10 μL of supernatant was applied to the HPLC system (L-7000 series; Hitachi High-Technologies Corporation, Tokyo, Japan) using a SUPELCOSIL LC-8 HPLC Column (Sigma–Aldrich Japan, Tokyo, Japan), an RC-10 reduction column (Shiseido Company, Tokyo, Japan), and an electrochemical detector (SI-2; Shiseido Company). The oxidation potential for the electrochemical detector was 600 mV. The mobile phase consisted of 50 mmol/L sodium perchlorate in methanol/2-propanol (100/10, v/v) with a flow rate of 1 mL/min. Serum total cholesterol was measured at baseline using the Liebermann-Burchard direct method at the Osaka Medical Center for Cancer and Cardiovascular Disease, an international member of the US National Cholesterol Reference Method Laboratory Network (CRMLN) [16].

For statistical analyses, we conducted conditional logistic analyses using SAS 9.1.3. Service Pack 4 (SAS Institute, Cary, NC, USA) with adjustments for body mass index, smoking status, alcohol consumption, diastolic blood pressure, total cholesterol, diabetes mellitus, and use of medication for hypertension or hypercholesterolemia. Since CoQ10 and total cholesterol were strongly correlated (Spearman r = 0.34), we also examined the association of the CoQ10/total cholesterol ratio with risk of disabling dementia. All probability values for the statistical tests were 2-tailed, and probability values below 0.05 were considered significant. Informed consent was obtained from community leaders and, verbally, from individual participants according to the guidelines of the Council for International Organizations of Medical Science [17]. The study was approved by the institutional review boards of the Osaka Center for Cancer and Cardiovascular Disease Prevention and of the University of Tsukuba.

3. Results

As shown in Table 1, the baseline characteristics did not differ materially between the cases and the non-cases, although diastolic blood pressure levels tended to be higher, and prevalence of cholesterol-lowering medication use, lower for cases than for non-cases.

Serum coenzyme Q10 was inversely associated with risk of incident dementia (Table 2). The multivariate odds ratios and 95% confidence intervals were 0.68 (0.26–1.78), 0.92 (0.33–2.56), and 0.23 (0.06–0.86), for individuals with the second, third, and highest quartiles of CoQ10, respectively, compared with the lowest quartile (P for trend = 0.05). A similar association was observed for the CoQ10/total cholesterol ratio. The respective odds ratios were 0.67 (0.25–1.78), 0.73 (0.28–1.92), and 0.21 (0.05–0.90) (P for trend = 0.04).

As supplemental analysis, we stratified dementia cases into those with history of stroke and those without it. Although the number of cases was limited, the associations were stronger for dementia without stroke for both serum CoQ10 and the CoQ10/total cholesterol ratio. The unadjusted odds ratios and 95% confidence intervals of dementia without stroke were 1.18 (0.37–3.75), 0.50 (0.15–1.70), and 0.46 (0.12–1.74) for individuals with the second, third, and highest quartiles of CoQ10 (P for trend = 0.13), and were 0.47 (0.15–1.48), 0.34 (0.11–1.09), and 0.24 (0.06–0.98) for respective quartiles of CoQ10/total cholesterol ratio (P for trend = 0.04). The corresponding odds ratios and 95% confidence intervals of dementia with stroke were 0.82 (0.26–2.57), 2.24 (0.63–7.96) and 0.35 (0.06–2.05) according to quartiles of CoQ10 (p for trend = 0.45), and were 1.68 (0.45–6.29), 2.05 (0.51–8.30) and 0.43 (0.06–2.97) according to quartiles of CoQ10/total cholesterol ratio (p for trend = 0.43).

4. Discussion

We found a strong inverse association between serum CoQ10 concentration and risk of disabling dementia in the Japanese population. To date, this is the first prospective study to examine the association between CoQ10 and incident dementia in a general setting.

Several animal studies have shown that CoQ10 may have a beneficial effect on dementia progression. In transgenic mice, dietary supplementation with CoQ10 reduced brain oxidative stress and deposition of amyloid plaque or amyloid-β and improved behavioral performance [11]. Rats with damaged hippocampi and cerebral cortices showed an adverse alteration in the markers of oxidative damage, but with supplementation with CoQ10, this alteration was reversed [8]. Thus, CoQ10 has been considered a
promising treatment for Alzheimer disease. However, a recent randomized control trial of patients with mild-to-moderate Alzheimer disease did not show that antioxidant treatment, including supplementation with high-dose CoQ10, improved the indices of markers of oxidative stress or of neurodegeneration in the cerebrospinal fluid[12]. Although this finding warrants confirmation by replication studies, when it is taken together with the findings of the present study, we assume that CoQ10 could have a more prominent impact on prevention, rather than on treatment, of dementia.

The limitations of this study include (1) the relatively small number of cases, although the associations were strong enough to be detected; (2) the diagnoses of disabling dementia conducted by attending physicians, although such diagnosis by attending physicians was previously validated[14]; and (3) the use of long-stored sera, although a previous study showed that the plasma CoQ10 value was unchanged after being deep-frozen and stored for 3 years[18]. When we excluded the serum samples collected before 1989 (23 cases and 46 matched controls excluded), the results were similar (not shown). Fourth limitation is that we did not classify dementia into Alzheimer type and vascular type. Instead, we have information on dementia with and without history of stroke. The associations seemed stronger for dementia without history of stroke, which needs to be confirmed by further studies. Last, we did not survey the dementia at baseline. However, we constructed the baseline at least 5 years prior to the beginning of dementia survey, so the possibility of reverse causation may be small.

The inverse association between serum CoQ10 levels and incident dementia did not directly assure that dietary intake of CoQ10 would prevent dementia. Furthermore, CoQ10 supplements were not generally available in Japan at the era of the baseline period (1984–1994). The impact of dietary or supplementary intake of CoQ10 was not tested in the present study, which must be examined by a randomized control trial in the future.

In conclusion, the serum level of CoQ10 was inversely associated with disabling dementia in this Japanese general population, which suggests that higher serum CoQ10 levels may have a beneficial effect on prevention of dementia.

Acknowledgments

The authors thank Kimiko Yokota, Yumi Shina, Miyuki Hori, Tomoko Tanaka, and Kumi Otsuka, for technical assistance. We also thank Ms Flaminia Miyamasu, Medical English Communications Center, University of Tsukuba, for editorial assistance. This work was supported by Health and Labour Science Research Grants for Dementia (H21-Ninchisho-Wakate-007, 2009–2012, and H24-Ninchisho-Wakate-003, 2012–2015), Ministry of Health, Labour and Welfare, Japan. We have no potential conflicts of interest to declare. The full list of CIRCS investigators is presented in reference [13].

References


# Table 2

<table>
<thead>
<tr>
<th>Men and women</th>
<th>Quartiles of serum coenzyme Q10 (nmol/L)</th>
<th>Multivariable OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
</tr>
<tr>
<td>Total disabling dementia</td>
<td>Q1</td>
<td>459</td>
</tr>
<tr>
<td>Number of cases</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>Number of non-cases</td>
<td>32</td>
<td>33</td>
</tr>
<tr>
<td>Matched OR (95%CI)</td>
<td>1.0</td>
<td>1.03 (0.47–2.29)</td>
</tr>
<tr>
<td>Multivariable OR (95%CI)</td>
<td>1.0</td>
<td>0.68 (0.26–1.78)</td>
</tr>
</tbody>
</table>

# References


